🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for ALK+ Non-Small-Cell Lung Carcinoma

A Real World Study of Ensartinib in Advanced ALK-positive NSCLC NCT05498064n/a1 site📍 Beijing Peking Union Medical College Hospital · Tests: Ensartinib A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy NCT06362369Phase 1, Phase 25 sites📍 Aurora📍 Lake Mary📍 Lebanon 7 Hills Pharma, LLC · Tests: Alintegimod, Ipilimumab, Nivolumab A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer NCT06868277Phase 3304 sites📍 La Mesa📍 Los Alamitos📍 Newark AstraZeneca · Tests: Rilvegostomig, Pembrolizumab A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC NCT06627647Phase 3301 sites📍 Mobile📍 Chandler📍 Phoenix AstraZeneca · Tests: Rilvegostomig, Pembrolizumab, Carboplatin, Cisplatin, Pemetrexed Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC NCT05950139Phase 1, Phase 21 site📍 Baltimore Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Tests: Peptide vaccine A Study to Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Exclusively Extracranial Disease Progression on Lorlatinib NCT06378892Phase 29 sites📍 Aviano📍 Florence📍 Lido di Camaiore Centro di Riferimento Oncologico - Aviano · Tests: Lorlatinib Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung Cancer NCT05284539Phase 21 site📍 Changsha Hunan Province Tumor Hospital · Tests: Pemetrexed, Cisplatin, Bevacizumab Plus Pembrolizumab Savolitinib Plus Docetaxel as 2L in EGFR/ALK/ROS1/MET ex14m-wildtype NSCLC With MET Overexpression NCT05777278Phase 1, Phase 21 site📍 Guangzhou The First Affiliated Hospital of Guangzhou Medical Universi… · Tests: Savolitinib, Docetaxel ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma NCT05014464Phase 21 site📍 Changsha Hunan Province Tumor Hospital · Tests: Crizotinib ctDNA-MRD Guided Consolidation Toripalimab in Stage IB-IIIA NSCLC NCT06426511Phase 21 site📍 Guangzhou Sun Yat-sen University · Tests: Toripalimab+Chemotherapy, Toripalimab+Chemotherapy followed by consolidation toripalimab Post Marketing Surveillance(PMS) Study of Lorviqua in Korea NCT05599412n/a1 site📍 Seoul Pfizer · Tests: Lorviqua Gilteritinib for the Treatment of ALK NSCLC NCT06225427Phase 13 sites📍 Los Angeles📍 Washington D.C.📍 Ann Arbor University of Michigan Rogel Cancer Center · Tests: Biopsy, Biospecimen Collection, Computed Tomography, Echocardiography, Gilteritinib Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels NCT05525338Phase 48 sites📍 Villejuif📍 Nijmegen📍 Maastricht University Medical Center Groningen · Tests: Alectinib QL1706 Combined With Chemotherapy in the Treatment of Immune-mediated NSCLC NCT07330596Phase 21 site📍 Hefei Anhui Provincial Cancer Hospital · Tests: QL1706 combined with Chemotherapy, Chemotherapy A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements NCT03093116Phase 1, Phase 2165 sites📍 Duarte📍 Glendale📍 La Jolla Turning Point Therapeutics, Inc. · Tests: Oral repotrectinib (TPX-0005) Immunotherapy Without Chemotherapy for Advanced Lung Cancer Patients With High PD-L1 Levels NCT07360743Phase 24 sites📍 Bordeaux📍 Boulogne-Billancourt📍 Nice UNICANCER · Tests: Pembrolizumab, Cemiplimab Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer NCT05765877Phase 21 site📍 Jinan Pingping Song · Tests: WX-0593 Tablets Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World Context NCT06487078NA32 sites📍 Toulouse📍 Paris📍 Aix-en-Provence Pfizer · Tests: Lorlatinib A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma NCT05456256Phase 216 sites📍 Beverly Hills📍 Fountain Valley📍 Los Alamitos Lantern Pharma Inc. · Tests: LP-300, Pemetrexed, Carboplatin Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLC NCT06092086Phase 21 site📍 Guangzhou Guangdong Association of Clinical Trials · Tests: Loratinib Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer NCT05142189Phase 145 sites📍 Lexington📍 Louisville📍 Baltimore BioNTech SE · Tests: BNT116, Cemiplimab, Docetaxel, Carboplatin, Paclitaxel A Study on Exploring the Abscopal Effect Induced by Different Radioimmunotherapy Combination Patterns in the Treatment of Non-Small Cell Lung Cancer With Multiple Metastases NCT06947694Phase 21 site📍 Chongqing Xinqiao Hospital of Chongqing · Tests: chemotherapy + PD-1 inhibitors, chemotherapy + PD-1 inhibitors, chemotherapy + PD-1 inhibitors, chemotherapy + PD-1 inh… Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC NCT06765109Phase 3159 sites📍 Glendale📍 Newport Beach📍 Orange Nuvalent Inc. · Tests: Neladalkib (NVL-655), Alectinib Efficacy and Safety of Ivonescimab Monotherapy as First-Line Treatment for PD-L1-Positive, Driver Gene-Negative, Locally Advanced or Metastatic NSCLC: A Multicenter, Prospective, Real-World Cohort Study NCT07696832n/a1 site📍 Guangzhou Guangdong Association of Clinical Trials · Tests: Ivonescimab Injection Alectinib Followed by Concomitant Consolidation Radiation Therapy in Advanced NSCLC With ALK-rearrangement (A-SAB) NCT05724004NA1 site📍 Stockholm Karolinska University Hospital · Tests: SBRT/SRS/radiation therapy Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy NCT03042221n/a1 site📍 Aurora University of Colorado, Denver Observation or Upfront Cranial RT in Oncogene Mutated NSCLC With Asymptomatic BM: A Phase III RCT NCT05236946Phase 31 site📍 Mumbai Tata Memorial Hospital · Tests: Stereotactic radiosurgery/whole brain radiotherapy, Tyrosine kinase inhibitor Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation NCT04322890Phase 21 site📍 Changsha Hunan Province Tumor Hospital · Tests: Osimertinib, Alectinib 150 MG, Crizotinib 250 MG, Savolitinib, Crizotinib., Chemotherapy Study on the Optimal Combination Pattern of the Combined Treatment of Radiotherapy and Immunotherapy for the Abscopal Effect in Non-Small Cell Lung Cancer (NSCLC) With Multiple Metastases NCT06953843Phase 21 site📍 Chongqing Xinqiao Hospital of Chongqing · Tests: Benmelstobart combined with chemotherapy, Benmelstobart combined with chemotherapy, Benmelstobart combined with chemoth… Adjuvant Therapy of Ensartinib in Stage IB-IIIA ALK-positive Non-small Cell Lung Cancer NCT05241028Phase 21 site📍 Shijiazhuang Hebei Medical University Fourth Hospital · Tests: Ensartinib
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy